Abstract
The clinical relevance of the receptor for advanced glycation end products (RAGE) and amphoterin expression was examined in 119 non-diabetic patients with colorectal carcinoma. Expression of RAGE was examined by immunohistochemistry and that of amphoterin by in situ hybridization. RAGE expression was observed in 55% (64/119) of the cases. RAGE positivity in Dukes' B, C and D cases was 19, 81 and 100%, respectively (p<0.0001). Amphoterin was expressed in most cases regardless of tumor stage. Survival analysis of Dukes' B and C cases showed a significantly poorer prognosis for patients with co-expression of RAGE and amphoterin than for patients without co-expression. The results suggest that co-expression of RAGE and amphoterin is closely associated with invasion and metastasis of colorectal cancer.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / metabolism*
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology
-
Colorectal Neoplasms / metabolism*
-
Colorectal Neoplasms / mortality
-
Colorectal Neoplasms / pathology
-
Glucuronidase / metabolism
-
Glycation End Products, Advanced / metabolism*
-
HMGB1 Protein / genetics*
-
Humans
-
Hyaluronan Receptors / metabolism
-
Immunohistochemistry
-
In Situ Hybridization
-
Ligands
-
Molecular Sequence Data
-
Neoplasm Invasiveness
-
Polymerase Chain Reaction
-
RNA, Messenger / metabolism
-
Receptor for Advanced Glycation End Products
-
Receptors, Immunologic / metabolism*
-
Survival Rate
Substances
-
Glycation End Products, Advanced
-
HMGB1 Protein
-
Hyaluronan Receptors
-
Ligands
-
RNA, Messenger
-
Receptor for Advanced Glycation End Products
-
Receptors, Immunologic
-
heparanase
-
Glucuronidase
Associated data
-
GENBANK/AB036432
-
GENBANK/X12597